相关实验视频
Updated: Jun 4, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
人工智能驱动的临床试验的进展,陷和影响
Dominika Wilczok1, Alex Zhavoronkov2,3,4
1Duke University, Durham, North Carolina, USA.
药物发现和开发 (AIDD) 中的人工智能 (AI) 已经看到大量投资,但临床成功很少. 这一观点分析了人工智能对制药研究进行革命的挑战和机会.
科学领域:
- 制药科学 制药科学
- 计算生物学 计算生物学
- 生物技术是生物技术.
背景情况:
- 自2010年代以来,大量投资流入了将人工智能 (AI) 应用于药物发现和开发 (AIDD).
- 尽管有大量的资源,但人工智能驱动的候选药物在人类临床试验中的进展有限,没有批准.
研究的目的:
- 批判性地检查阻碍人工智能在药物发现和开发方面的发展障碍.
- 识别和突出利用人工智能的关键机会,以改变制药研发格局.
主要方法:
- 这是一篇透视性的文章,涉及到对人工智能在药物发现中的当前状态的批判性分析.
- 文献综述和专家意见综合对挑战和未来的方向.
主要成果:
- 药物发现人工智能的进展受到几个关键挑战的阻碍.
- 有很多机会来增强人工智能对药物发现和开发管道的影响.
结论:
- 克服当前的挑战对于实现人工智能的全部潜力至关重要,以加速新疗法的交付.
- 对特定机会的战略重点可以推动人工智能驱动的药物发现和开发的变革性变化.
更多相关视频
09:00TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
Published on: April 13, 2021
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
相关概念视频
Clinical Trials
There are four phases in a clinical trial. A phase one...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Current Trends in Nursing II
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Blinding
Methods of Documentation III: PIE